**§ 62.301 Payment of fees and other charges.**

Fees and other charges for QSVP services shall be paid in accordance with the following provisions. Upon receipt of billing for fees and other charges, the applicant shall remit payment within 10 business days by check, electronic funds transfer, draft, or money order made payable to USDA, AMS, in accordance with directions on the billing. Fees and charges shall be paid in advance if required by the auditor or other authorized USDA official.

**Miscellaneous**

**OMB Control Number**

**§ 62.400 OMB control number assigned pursuant to the Paperwork Reduction Act.**

The information collection and recordkeeping requirements of this part have been approved by OMB under 44 U.S.C. Chapter 35 and have been assigned OMB Control Number 0581–0124.

Dated: October 4, 2005.

**Lloyd C. Day,**

*Administrator, Agricultural Marketing Service.*

[FR Doc. 05–20310 Filed 10–7–05; 8:45 am]

**BILLING CODE 3410–02–P**

## SMALL BUSINESS ADMINISTRATION

### 13 CFR Part 126

**RIN 3245–AF31**

### HUBZone Program; Corrections

**AGENCY:** U.S. Small Business Administration (SBA).

**ACTION:** Correcting amendments.

**SUMMARY:** The U.S. Small Business Administration (SBA) is correcting an improper citation within the interim rule that appeared in the **Federal Register** on August 30, 2005, which amends SBA's HUBZone program regulations.

**DATES:** Effective October 11, 2005.

**FOR FURTHER INFORMATION CONTACT:** Michael McHale, Associate Administrator, HUBZone Program, at (202) 205–6731 or by e-mail at: *michael.mchale@sba.gov.*

**SUPPLEMENTARY INFORMATION:**

**Background**

On August 30, 2005, at 79 FR 51243, the SBA published an interim final rule amending SBA's HUBZone, 8(a) Business Development, Government Contracting and Size Standard regulations. This rule implemented provisions of the Small Business Act including the Consolidated Appropriations Act, 2005, specifically, Subtitle E of Division K entitled the Small Business Reauthorization and Manufacturing Assistance Act of 2004.

**Need for Correction**

Since publication, SBA has discovered that this interim rule inadvertently stated SBA's intent to revise § 126.306 (found at 70 FR 51250) when it should have cited specifically to § 126.306(a). SBA intended to revise only subsection (a) leaving the other subsections unchanged.

**List of Subjects in 13 CFR Part 126**

Administrative practice and procedure, Government procurement, Small businesses.

■ Accordingly, 13 CFR part 126 is corrected by making the following correcting amendments:

## PART 126—HUBZONE PROGRAM

■ 1. The authority citation for part 126 continues to read as follows:

**Authority:** 15 U.S.C. 632(a), 632(j), 632(p) and 657a.

■ 2. Revise the first and last sentences of § 126.306(a) as follows:

**§ 126.306 How will SBA process this certification?**

(a) The AA/HUB or designee is authorized to approve or decline certifications. * * * The decision of the AA/HUB or designee is the final agency decision.

* * * * *

Dated: September 30, 2005.

**Allegra McCullough,**

*Associate Deputy Administrator/Office of Government Contracting and Business Development.*

[FR Doc. 05–20188 Filed 10–7–05; 8:45 am]

**BILLING CODE 8025–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Parts 310 and 341

**[Docket No. 2004N–0289]**
**RIN 0910–AF34**

### Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph for Over-the-Counter Nasal Decongestant Drug Products

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the final monograph (FM) for over-the-counter (OTC) nasal decongestant drug products (drug products used to relieve nasal congestion due to a cold, hay fever, or other upper respiratory allergies) to remove the indication ''for the temporary relief of nasal congestion associated with sinusitis'' and to prohibit use of the terms ''sinusitis'' and ''associated with sinusitis'' elsewhere on the labeling. This final rule is part of FDA's ongoing review of OTC drug products.

**DATES:** *Effective Date*: This regulation is effective April 11, 2007.

*Compliance Dates*: The compliance date for products with annual sales less than $25,000 is October 11, 2007. The compliance date for all other products is April 11, 2007.

**FOR FURTHER INFORMATION CONTACT:** Michael T. Benson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Silver Spring, MD 20993, 301–796–2090.

**SUPPLEMENTARY INFORMATION:**

**I. Background**

In the **Federal Register** of August 2, 2004 (69 FR 46119), FDA published a proposed rule to amend the FM for OTC nasal decongestant drug products to remove the indication ''for the temporary relief of nasal congestion associated with sinusitis'' and to prohibit use of the terms ''sinusitis'' and ''associated with sinusitis'' elsewhere on the labeling. Recent publications (Refs. 1 and 2) indicate that prospective studies on the role of nasal decongestants in the treatment of sinusitis are lacking, and the data on their use as an adjunct in the treatment of sinusitis are limited and controversial. Despite the lack of evidence for their use, nasal decongestants are recommended or prescribed by health care providers as adjunctive therapy for sinusitis. This treatment occurs within a physician-patient relationship and should not be construed as evidence that consumers should self-diagnose and self-manage sinusitis. In addition, there is preclinical evidence that topical nasal decongestants may have a negative effect on the resolution of sinusitis, as they may increase the degree of sinus inflammation (Ref. 3). Due to the current labeling, FDA is concerned that consumers use OTC nasal decongestant drug products (both oral and topical) to treat symptoms associated with